On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Infuses Cannabis Industry, Delivers Results with Innovative Drug Delivery Platform

  • Global legal cannabis market projected to surpass $146 billion by end of 2025
  • Cannabinoid-infused edibles, concentrates represent fastest-growing segment of industry
  • Lexaria’s patented technology improves bio-absorption and bioavailability of active ingredients while masking unpleasant taste
  • Lucrative licensing business model includes agreements to enhance cannabinoid (CBD) delivery before year-end 2018

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its proprietary technology found in the company’s drug delivery platform DehydraTECH has application for several subsets of the cannabis industry and other pharmacological verticals. As a technology proven to deliver increased intestinal absorption rates and higher bioavailability for a number of bioactive compounds, the DehydraTECH drug delivery platform could be a game changer for several industries, including the recreational and medical cannabis markets, according to a recent article (http://cnw.fm/4QPoL). While cannabis flower has been the early focus, cannabinoid-infused edibles and concentrates represent the fastest-growing segments of the $100+ billion industry, the article points out.

“We are focused on making ingestible or edible bioactive substances taste better, smell better, act faster and enhance potency,” Lexaria President John Docherty, a trained pharmacologist and toxicologist who is also the former president and chief operations officer of Helix BioPharma Corp., stated in a news release.

Lexaria’s DehydraTECH employs a patented, cost-effective delivery mechanism leveraging lipophilic agents that improves the bio-absorption and bioavailability of ingestible substances, as well as their taste and smell. That’s no small task when it comes to some of the pungent terpenes essential to the cannabis plant, as many cannabis consumers know well. Terpenes are aromatic components of the cannabis plant’s essential oils, and they also play an important therapeutic role, according to an article on GreenState.com (http://cnw.fm/98yD7).

Lexaria’s disruptive DehydraTECH drug delivery platform is protected by a robust suite of patents granted or pending worldwide. It has been proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules – such as those contained in cannabinoids (CBD), nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. DehydraTECH offers a healthier, oral ingestion alternative to other delivery methods, such as smoking, which has known negative consequences, to quickly and effectively deliver the bioactive substances that cannabis and nicotine consumers are seeking, as Lexaria points out in detail on its website.

Another key to Lexaria’s success is the fact that its technology can be licensed to improve existing drug delivery through orally-ingested products or to create new ones. The DehydraTECH drug delivery platform has limitless commercial applications for formulating and delivering lipophilic drug payloads. The company’s strategic intellectual property (IP) portfolio is growing, with three more patents in Australia and two Notices of Allowance from the U.S. Patent and Trademark Office and several more expected prior to year-end 2018 (http://cnw.fm/lxC2F).

Lexaria’s IP portfolio already includes a patent for oral delivery of all cannabinoids, and it has licensed its products to numerous cannabis companies, including a maker of cannabis-infused chocolates in Colorado, a Canada-based developer of cannabis wines and beers and a new Canadian company focused on cannabis-infused edibles. With projections of a global legal cannabis market coming in at more than $146 billion by 2025 (http://cnw.fm/5UUtK), Lexaria Bioscience is poised to deliver a welcome technology to this booming, quickly expanding space.

For more information, visit the company’s website at www.LexariaBioscience.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Archives

Select A Month

Contact us: 303.498.7722